LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival

BMC Cancer

Sabine Kasimir-Bauer³  Rainer Kimmig³  Micaela Poetsch²  Pauline Wimberger³  Heidi Schwarzenbach¹  Jan Dominik Kuhlmann³ 

[1]Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

[2]Institute of Legal Medicine, University Hospital of Essen, Essen, Germany

[3]Department of Gynecology and Obstetrics, University Hospital of Essen, Hufelandstrasse 55, Essen, D-45122, Germany

关键词: Tumor suppressor genes;    DNA-fractionation;    Disseminated tumor cells;    Loss of heterozygosity;    Circulating DNA;   

Others  :  1080283
DOI  :  10.1186/1471-2407-12-325

 received in 2012-03-30, accepted in 2012-07-18,  发布年份 2012

【 摘 要 】

Background

We recently showed that LOH proximal to M6P/IGF2R locus (D6S1581) in primary ovarian tumors is predictive for the presence of disseminated tumor cells (DTC) in the bone marrow (BM). For therapy-monitoring, it would be highly desirable to establish a blood-based biomarker. Therefore, we quantified circulating DNA (cirDNA) in sera of 63 ovarian cancer patients before surgery and after chemotherapy, measured incidence of LOH at four cancer-relevant chromosomal loci, correlated LOH with tumor cell spread to the BM and evaluated prognostic significance of LOH.

Methods

cirDNA was fractionated into high- and low molecular-weight fraction (HMWF, LMWF) for LOH-profiling, utilizing PCR-based fluorescence microsatellite analysis. BM aspirates were analyzed for DTC by immunocytochemistry using the pan-cytokeratin antibody A45-B/B3.

Results

cirDNA levels in the HMWF before surgery were predictive for residual tumor load (p = 0.017). After chemotherapy, we observed a significant decline of cirDNA in the LMWF (p = 0.0001) but not in the HMWF. LOH was prevalently detected in the LMWF with an overall frequency of 67%, only moderately ablating after chemotherapy (45%). Before surgery, LOH in the LMWF at marker D10S1765 and D13S218 significantly correlated with tumor grading and FIGO stage (p = 0.033, p = 0.004, respectively). In both combined fractions, LOH at D6S1581 additionally associated with overall survival (OS) (p = 0.030). Moreover, solely LOH at D10S1765 in LMWF after therapy correlated with DTC in BM after therapy (p = 0.017).

Conclusion

We demonstrate the applicability and necessity of DNA-fractionation prior to analyzing circulating LOH and identify LOH at D10S1765 and D6S1581 as novel blood-based biomarkers for ovarian cancer, being relevant for therapy-monitoring.

【 授权许可】

   
2012 Kuhlmann et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1 .

Figure 2 .

Figure 3 .

【 参考文献 】

• [1]Goodman MT, Howe HL, Tung KH, Hotes J, Miller BA, Coughlin SS, Chen VW: Incidence of ovarian cancer by race and ethnicity in the United States, 1992–1997. Cancer 2003, 97(10 Suppl):2676-2685.
• [2]du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, et al.: 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005, 16(Suppl 8):viii7-viii12.
• [3]du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009, 115(6):1234-1244.
• [4]Martin LP, Schilder RJ: Management of recurrent ovarian carcinoma: current status and future directions. Semin Oncol 2009, 36(2):112-125.
• [5]Kuhlmann JD, Schwarzenbach H, Otterbach F, Heubner M, Wimberger P, Worm KH, Kimmig R, Kasimir-Bauer S: Loss of heterozygosity proximal to the M6P/IGF2R locus is predictive for the presence of disseminated tumor cells in the bone marrow of ovarian cancer patients before and after chemotherapy. Genes Chromosomes Cancer 2011, 50(8):598-605. Epub 2011 May 11
• [6]Fleischhacker M, Schmidt B: Circulating nucleic acids (CNAs) and cancer–a survey. Biochim Biophys Acta 2007, 1775(1):181-232.
• [7]Schwarzenbach H, Hoon DS, Pantel K: Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011, 11(6):426-437.
• [8]Wimberger P, Roth C, Pantel K, Kasimir-Bauer S, Kimmig R, Schwarzenbach H: Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients. Int J Cancer 2011, 128(11):2572-2580. Epub 2010 Oct 26
• [9]Stroun M, Anker P, Lyautey J, Lederrey C, Maurice PA: Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 1987, 23(6):707-712.
• [10]Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M: Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989, 46(5):318-322.
• [11]Kuang Y, Rogers A, Yeap BY, Wang L, Makrigiorgos M, Vetrand K, Thiede S, Distel RJ, Janne PA: Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 2009, 15(8):2630-2636.
• [12]Chen XQ, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, Lederrey C, Anker P: Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med 1996, 2(9):1033-1035.
• [13]Coulet F, Blons H, Cabelguenne A, Lecomte T, Lacourreye O, Brasnu D, Beaune P, Zucman J, Laurent-Puig P: Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. Cancer Res 2000, 60(3):707-711.
• [14]Wang Q, Larson PS, Schlechter BL, Zahid N, Finnemore E, de las Morenas A, Blanchard RA, Rosenberg CL: Loss of heterozygosity in serial plasma DNA samples during follow-up of women with breast cancer. Int J Cancer 2003, 106(6):923-929.
• [15]Muller I, Beeger C, Alix-Panabieres C, Rebillard X, Pantel K, Schwarzenbach H: Identification of loss of heterozygosity on circulating free DNA in peripheral blood of prostate cancer patients: potential and technical improvements. Clin Chem 2008, 54(4):688-696.
• [16]Hung T, Mak K, Fong K: A specificity enhancer for polymerase chain reaction. Nucleic Acids Res 1990, 18(16):4953.
• [17]Chevet E, Lemaitre G, Katinka MD: Low concentrations of tetramethylammonium chloride increase yield and specificity of PCR. Nucleic Acids Res 1995, 23(16):3343-3344.
• [18]Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C, Schindlbeck C, Wallwiener D, Borgen E, Naume B, et al.: A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 2006, 107(5):885-892.
• [19]Borgen E, Naume B, Nesland JM, Kvalheim G, Beiske K, Fodstad O, Diel I, Solomayer EF, Theocharous P, Coombes RC, et al.: Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1999, 1(5):377-388.
• [20]Wang M, Block TM, Steel L, Brenner DE, Su YH: Preferential isolation of fragmented DNA enhances the detection of circulating mutated k-ras DNA. Clin Chem 2004, 50(1):211-213.
• [21]Nakamura T, Sakai T, Nariya S: Cell death in colorectal polyps as evaluated by in situ 3'-tailing reaction and its relationship to BCL-2 expression. Pathol Int 1995, 45(10):721-728.
• [22]Schulte-Hermann R, Bursch W, Grasl-Kraupp B, Torok L, Ellinger A, Mullauer L: Role of active cell death (apoptosis) in multi-stage carcinogenesis. Toxicol Lett 1995, 82–83:143-148.
• [23]Arai N, Mitomi H, Ohtani Y, Igarashi M, Kakita A, Okayasu I: Enhanced epithelial cell turnover associated with p53 accumulation and high p21WAF1/CIP1 expression in ulcerative colitis. Mod Pathol 1999, 12(6):604-611.
• [24]Anker P, Mulcahy H, Chen XQ, Stroun M: Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999, 18(1):65-73.
• [25]Chun FK, Muller I, Lange I, Friedrich MG, Erbersdobler A, Karakiewicz PI, Graefen M, Pantel K, Huland H, Schwarzenbach H: Circulating tumour-associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU Int 2006, 98(3):544-548.
• [26]Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, Diaz LA Jr, Goodman SN, David KA, Juhl H, et al.: Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 2005, 102(45):16368-16373.
• [27]Hamana K, Uzawa K, Ogawara K, Shiiba M, Bukawa H, Yokoe H, Tanzawa H: Monitoring of circulating tumour-associated DNA as a prognostic tool for oral squamous cell carcinoma. Br J Cancer 2005, 92(12):2181-2184.
• [28]Rawnaq T, Schwarzenbach H, Schurr PG, Freise K, Brandl S, Izbicki JR, Kaifi JT: Monitoring of loss of heterozygosity in serum microsatellite DNA among patients with gastrointestinal stromal tumors indicates tumor recurrence. J Surg Res 2011, 169(1):31-35.
• [29]Schwarzenbach H, Muller V, Beeger C, Gottberg M, Stahmann N, Pantel K: A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer. Breast Cancer Res 2007, 9(5):R66. BioMed Central Full Text
• [30]Silva JM, Garcia JM, Dominguez G, Silva J, Miralles C, Cantos B, Coca S, Provencio M, Espana P, Bonilla F: Persistence of tumor DNA in plasma of breast cancer patients after mastectomy. Ann Surg Oncol 2002, 9(1):71-76.
• [31]Gonzalez R, Silva JM, Sanchez A, Dominguez G, Garcia JM, Chen XQ, Stroun M, Provencio M, Espana P, Anker P, et al.: Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance. Ann Oncol 2000, 11(9):1097-1104.
• [32]Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, Luk L, Titley I, Carden CP, Box G, et al.: Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther 2011, 10(2):325-335.
• [33]Zhang S, Yu D: PI(3)king apart PTEN’s role in cancer. Clin Cancer Res 2010, 16(17):4325-4330.
• [34]Yang H, Kong W, He L, Zhao JJ, O’Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, et al.: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008, 68(2):425-433.
• [35]Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR: Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 2004, 64(9):3014-3021.
• [36]Makhija S, Sit A, Edwards R, Aufman K, Weiss H, Kanbour-Shakir A, Gooding W, D’Angelo G, Ferrell R, Raja S, et al.: Identification of genetic alterations related to chemoresistance in epithelial ovarian cancer. Gynecol Oncol 2003, 90(1):3-9.
• [37]Lee AV, Hilsenbeck SG, Yee D: IGF system components as prognostic markers in breast cancer. Breast Cancer Res Treat 1998, 47(3):295-302.
• [38]Oates AJ, Schumaker LM, Jenkins SB, Pearce AA, DaCosta SA, Arun B, Ellis MJ: The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene. Breast Cancer Res Treat 1998, 47(3):269-281.
• [39]Wood TL, Richert MM, Stull MA, Allar MA: The insulin-like growth factors (IGFs) and IGF binding proteins in postnatal development of murine mammary glands. J Mammary Gland Biol Neoplasia 2000, 5(1):31-42.
• [40]De Souza AT, Yamada T, Mills JJ, Jirtle RL: Imprinted genes in liver carcinogenesis. FASEB J 1997, 11(1):60-67.
• [41]Rey JM, Theillet C, Brouillet JP, Rochefort H: Stable amino-acid sequence of the mannose-6-phosphate/insulin-like growth-factor-II receptor in ovarian carcinomas with loss of heterozygosity and in breast-cancer cell lines. Int J Cancer 2000, 85(4):466-473.
• [42]Bookman MA: Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist 1999, 4(2):87-94.